



17·18
February 2022

*Innovation
in Breast Cancer*

iBC 2022

DIRECTOR

Miguel Martín
*Hospital General Universitario Gregorio Marañón
Madrid*

Innovation in Breast Cancer – iBC 2022

THURSDAY **17th** February 2022

16:30-16:45 **Introduction**
Miguel Martin, Hospital General Universitario Gregorio Marañón, Madrid, Spain

SESSION I: BIOMARKERS
Chair: Ángel Guerrero, Instituto Valenciano de Oncología (IVO), Valencia, Spain

16:45-17:05 **ESR1 mutations in estrogen receptor positive breast cancer**
Rachel Schiff, Baylor College of Medicine, Houston, USA

17:05-17:25 **Mechanisms of resistance to CDK 4/6 inhibition**
Rinath Jeselsohn, Dana-Farber/ Harvard Cancer Institute, Boston, USA

17:25-17:45 **Relevance of PIK3CA mutations in advanced breast cancer**
TO BE CONFIRMED

17:45-18:15 **Discussion**

18:15-18:30 **Break**

SESSION II: NEW DRUGS IN BREAST CANCER
Chair: Luis Costa, Hospital de Santa María, Lisbon, Portugal

18:30-18:50 **Immunoconjugates for breast cancer: recent advances**
Shanu Modi, Memorial Sloan Kettering Cancer Center, New York, USA

18:50-19:10 **TKI inhibitors in HER2-positive breast cancer**
Sandra Swain, Georgetown University Medical Center, Washington D.C., USA

19:10-19:30 **Selective Estrogen Receptor Degradors (SERDs): A New Strategy for Estrogen Receptor Positive Breast Cancer**
Erika P. Hamilton, Tennessee Oncology, Nashville, USA

19:30-20:00 **Discussion**

FRIDAY **18th** February 2022

SESSION III: TREATMENT OF BREAST CANCER
Chair: Ander Urruticoechea, Onkologikoa, San Sebastián, Spain

16:00-16:20 **Pathological response as predictor of outcome after neoadjuvant chemotherapy for operable breast cancer**
Fraser W Symmans, University of Texas M.D. Anderson Cancer Center, Houston, USA

16:20-16:40 **PARP-1 inhibitors in early breast cancer**
Andrew Tutt, Breast Cancer Now Toby Robins Research Centre, London, UK

16:40-17:00 **Defining high-risk criteria for operable ER+/HER2- breast cancer**
Joyce o'Shaughnessy, Texas Oncology, Dallas, US

17:00-17:30 **Discussion**

17:30-17:45 **Break**

SESSION IV: HER2-NEGATIVE BREAST CANCER
Chair: José Enrique Ales, Hospital Ntra. Sra. de Sonsoles, Ávila, Spain

17:45-18:05 **Adjuvant endocrine treatment of premenopausal HR+/HER2- breast cancer patients**
Olivia Pagani, Dana-Farber/ Harvard Cancer Institute, Boston, USA

18:05-18:25 **Sequencing therapies in metastatic HR-positive /HER2-negative breast cancer**
Miguel Martin, Hospital General Universitario Gregorio Marañón, Madrid, Spain

18:25-18:45 **Advances in the neo/adjuvant treatment of triple negative breast cancer**
Hope Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA

18:45-19:15 **Discussion**

19:15 **Closing remarks**
Miguel Martin, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Innovation in Breast Cancer - iBC 2022

Sponsors

Platinum



Gold



Silver



Bronze



Other collaborations



Under the auspices of



Organized by



Accreditation

Continuing Education Credits requested to the Spanish National Health System

Symposium secretariat



Tel.: (+34) 91 372 02 03
e-mail: ibc@doctaforum.com
www.innovationinbreastcancer.com